TITLE

Plasma tumour necrosis factor alpha in cystic fibrosis

AUTHOR(S)
Norman, D; Elborn, J S; Cordon, S M; Rayner, R J; Wiseman, M S; Hiller, E J; Shale, D J
PUB. DATE
February 1991
SOURCE
Thorax;Feb1991, Vol. 46 Issue 2, p91
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
66072236

 

Related Articles

  • Adalimumab.  // Reactions Weekly;8/24/2013, Issue 1466, p5 

    An abstract of the article "Lichen planopilaris: The paradoxical role of tumour necrosis factor alpha antagonists," by M. Walsh and colleagues is presented.

  • ROLE OF TUMOUR NECROSIS FACTOR α RECEPTOR SUBTYPES IN TUMOUR NECROSIS FACTOR-INDUCED MOUSE LUNG MICROVASCULAR ENDOTHELIAL CELL ACTIVATION.  // Thorax;Dec2008 Supplement 7, Vol. 63, pA141 

    An abstract of the article "Role of Tumour Necrosis Factor Alpha Receptor Subtypes in Tumour Necrosis Factor-Induced Mouse Lung Microvascular Endothelial Cell Activation," by S. Bertok and colleagues is presented.

  • Rheumatoid arthritis drug could prevent kidney cysts. Tanday, Sanjay // GP: General Practitioner;6/20/2008, p5 

    The article presents the findings of a study by Rong Li from the Institute for Medical Research and colleagues which showed that a drug could offer new hope for patients with polycystic kidney disease. Researchers analysed cyst fluid taken from the kidneys of 10 patients with polycystic kidney...

  • Association of TNF-α Gene Variants With Clinical Manifestation of Cystic Fibrosis Patients of Iranian Azeri Turkish Ethnicity. Khorrami, Aziz; Bonyadi, Mortaza; Rafeey, Mandana; Omrani, Omid // Iranian Journal of Pediatrics;Feb2015, Vol. 25 Issue 1, p1 

    The article reviews a study from Tabriz, Iran that assessed the effect of non-cystic fibrosis (CF) transmembrane conductance regulator (CFTR) genes on the clinical phenotype of CF, two polymorphic sites of the Tumor Necrosis Factor-alpha (TNF-α). Topics discussed include the study finding...

  • Adalimumab use in pregnancy. Vesga, L.; Terdiman, J. P.; Mahodevan, U. // Gut;Jun2005, Vol. 54 Issue 6, p890 

    Presents a letter about infliximab, a chimeric antibody to tumour necrosis factor alpha that has demonstrated efficacy for the induction and main- tenance of remission in patients with Crohn's disease.

  • Adalimumab/etanercept/infliximab.  // Reactions Weekly;Jul2015, Vol. 1558 Issue 1, p18 

    The article presents case reports of 15 patients who developed tuberculosis after receiving tumour necrosis factor (TNF)-alpha inhibitors.

  • Infliximab.  // Reactions Weekly;Dec2014, Vol. 1530 Issue 1, p122 

    An abstract of the article "Importance of tuberculosis screening before inhibiting tumour necrosis factor-alpha therapy," by A. Garcia-Lopez and colleagues is presented.

  • Variants in mannose-binding lectin and tumour necrosis factor α affect survival in cystic fibrosis. Buranawuti, Kitti; Boyle, Michael P.; Cheng, Suzanne; Steiner, Lori L.; McDougal, Kathryn; Fallin, M. Daniele; Merlo, Christian; Zeitlin, Pamela L.; Rosenstein, Beryl J.; Mogayzel Jr., Peter J.; Xinjing Wang; Cutting, Garry R. // Journal of Medical Genetics;Mar2007, Vol. 44 Issue 3, p209 

    Background: Patients with cystic fibrosis with the same mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene differ widely in survival suggesting other factors have a substantial role in mortality. Objective: To determine if the genotype distribution of variants in...

  • Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. Lionaki, Sofia; Siamopoulos, Kostas; Theodorou, Ioanna; Papadimitraki, Eva; Bertsias, George; Boumpas, Dimitrios; Boletis, John // Nephrology Dialysis Transplantation;Jul2009, Vol. 24 Issue 7, p2144 

    Background. Tumour necrosis alpha has been implicated in the pathogenesis of autoimmune disorders was to evaluate the safety, tolerability and potential efficacy of the tumour necrosis factor alpha (TNF-α) inhibitor, etanercept (ET), in patients with idiopathic membranous nephropathy (MN).

  • Adalimumab/etanercept/methotrexate.  // Reactions Weekly;4/19/2008, Issue 1198, p4 

    The article describes the cases of patients with seropositive rheumatoid arthritis who were receiving methotrexate in combination with etanercept or adalimumab. The patients developed increasing dyspnoea and were diagnosed with interstitial pneumonitis within 8-24 weeks of etanercept or...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics